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Abstract: Cardiovascular diseases are a large contributor to causes of early death in 
developed countries. Some of these conditions, such as sudden cardiac death and atrial 
fibrillation, stem from arrhythmias—a spectrum of conditions with abnormal electrical 
activity in the heart. Genome-wide association studies can identify single nucleotide 
variations (SNVs) that may predispose individuals to developing acquired forms of 
arrhythmias. Through manual curation of published genome-wide association studies, we 
have collected a comprehensive list of 75 SNVs associated with cardiac arrhythmias. Ten 
of the SNVs result in amino acid changes and can be used in proteomic-based detection 
methods. In an effort to identify additional non-synonymous mutations that affect the 
proteome, we analyzed the post-translational modification S-nitrosylation, which is known 
to affect cardiac arrhythmias. We identified loss of seven known S-nitrosylation sites due 
to non-synonymous single nucleotide variations (nsSNVs). For predicted nitrosylation sites 
we found 1429 proteins where the sites are modified due to nsSNV. Analysis of the 
predicted S-nitrosylation dataset for over- or under-representation (compared to the 
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complete human proteome) of pathways and functional elements shows significant 
statistical over-representation of the blood coagulation pathway. Gene Ontology (GO) analysis 
displays statistically over-represented terms related to muscle contraction, receptor activity, 
motor activity, cystoskeleton components, and microtubule activity. Through the genomic 
and proteomic context of SNVs and S-nitrosylation sites presented in this study, 
researchers can look for variation that can predispose individuals to cardiac arrhythmias. 
Such attempts to elucidate mechanisms of arrhythmia thereby add yet another useful 
parameter in predicting susceptibility for cardiac diseases. 
Keywords: cardiac arrhythmia; SNP; genome-wide association; proteomics; next-generation 
sequencing; S-nitrosylation; cysteine; nsSNV; biocuration 
 
1. Introduction 
Cardiac arrhythmias encompass a range of conditions in which the normal rhythm of the heart is 
disrupted. The conditions include sudden cardiac death (SCD) and atrial fibrillation (AF), the most 
common form of arrhythmia [1,2]. The causes of arrhythmias such as AF are multifaceted and this 
presents difficulties in their treatment [3]. The number of Americans afflicted with arrhythmia is 
expected to increase as the population ages. Consequently, understanding the exact mechanisms of the 
disease and developing treatments is important. 
DNA sequencing has evolved from its beginnings in the Sanger method. Now, next-generation 
sequencing (NGS) technologies allow the sequencing of millions of fragments of DNA in unison from 
a single sample. This process of parallel sequencing allows the whole genome to be sequenced in less 
than a day and is expected to be used in clinics in the near future [4]. Advances in DNA sequencing and 
genome-wide association studies are impacting detection, management, and treatment of diseases [5–8]. 
Several studies have investigated mutations and their associations with cardiac diseases. For example, 
long QT-syndrome (LQTS) is a disease characterized by prolonged repolarization of the heartbeat [9]. 
Research has shown that LQTS stems from mutations in genes encoding cardiac ion channels [10]. 
Over 100 mutations have been identified in 5 separate cardiac ion channel genes [9,10]. Other cardiac 
channelopathies, or disorders of the heart channel, affect normal cardiac rhythm in individuals [11]. 
Heritable cardiac arrhythmias, acquired from genetic alterations of these ion channels involved in 
cardiac heart rhythm, predispose affected individuals to sudden death [11]. Research on sudden cardiac 
death (SCD), which mainly results from severe ventricular arrhythmias, shows that a majority of 
mutations are found in the coding regions of ion channel units and key regulatory proteins. These 
mutations often lead to ion channel dysfunctions or affect biophysical properties of ion channels 
involved in normal heart function [12]. Further, computer modeling and simulations of cardiac 
myocytes have enabled scientists to represent variations in gene expression and allows them to 
reconstruct the effects of mutations characterized by functional changes in proteins [13]. Similar to 
DNA sequencing, proteomics technologies are also rapidly improving [14]. It is now possible to  
use proteomic technologies in conjunction with genomic technologies to detect and/or validate 
nsSNVs [15,16]. Such validation is critical to distinguish between inherited variations, somatic DNA 
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and RNA modifications [17]. Therefore, having a list of amino acid changes that are potentially related 
to a specific disease can be of immense value as priority targets for proteomic validation.  
One method for studying arrhythmias is investigating the genetic roots of the condition. This report 
presents the SNVs discovered or confirmed to have associations with arrhythmia over the past twenty 
years through genome-wide association and replication studies. Table 1 shows ten amino acid 
changing mutations, which can be detected using modern proteomic technologies [18]. While the 
variations are contained within a range of genes, the report further investigates two genes in particular. 
The first is NOS1AP, the most represented gene in Table S1, with 12 SNPs. The second gene is 
KCNN3, which hosts one of the exonic variants. 
Table 1. Summary of variant information from Table S1. 
Gene Number of Variations Chromosome Number Amino Acid Change Gene Description 
SCN10A 2 3 V1073A Sodium ion channel 
HEY2 1 6 0 Cardiovascular helix-loop-helix factor 1 
SCN5A 5 3 S1103Y, H558R Sodium ion channel 
TBX5 1 12 0 T-box transcription factor 
NOS1AP 12 1 0 Nitric oxide synthase 1 adaptor protein 
ATP1B1 2 1 0 Sodium/potassium-transporting ATPase subunit beta-1 
ZFHX3 3 16 0 Zinc finger homeobox protein 3 
KCNN3 3 1 N44N Small conductance potassium channel 
KCNJ2 2 17 0 Potassium ion channel 
XYLB 3 3 0 Energy metabolism 
EXOG 3 3 0 Endonuclease 
ACVR2B 3 3 0 Activin Receptor 
RNF207 1 1 G603A Ring finger protein 
PLN 2 6 0 Cardiac Muscle 
KCNH2 5 7 K897T, K557T Potassium voltage gated channel 
KCNQ1 4 11 G643S Potassium voltage gated channel 
LITAF 1 16 0 DNA binding protein 
NDRG4 1 16 0 Mitogenic signalling 
AGTR1 1 3 0 Angiotensis II receptor 
KNG1 1 3 0 Kininogen 
KCNE1 3 21 D85N, S38G Potassium voltage gated channel 
KCNE4 1 2 D196E Potassium voltage-gated channel 
In an attempt to identify more amino acid changing variations potentially connected to the disease, 
we investigated the post-translational modification (PTM) nitrosylation. S-nitrosylation involves 
covalent attachment of Nitric Oxide (NO) to the thiol side chain of cysteine to form an S-nitrosothiol 
(SNO) [19]. NO is a well-known signaling molecule in the cardiovascular system and its role in 
cardiovascular diseases has been established [20]. S-nitrosylation is a reversible and selective PTM 
which regulates protein activity, cellular signal transduction, localization, and stability [19,21]. 
Modified levels of SNO proteins in the blood have been associated with high risks in patients with 
cardiovascular diseases [19]. Several studies have investigated these associations. Massy et al. found 
elevated plasma SNO levels in patients undergoing chronic hemodialysis predict cardiovascular 
outcomes [22]. Another study investigated NO as an endocrine vasoregulator in red blood cells and the 
potential impact NO plays in congestive heart failure [23]. In addition to nitrosylation other PTMs, 
such as glycosylation and phosphorylation, are also known to maintain the cardiac rhythm [12]. 
Current studies examine the association between acquired arrhythmias and PTMs of the cardiac 
sodium channel, which is involved in cardiac action potentials [24]. Cutler et al. demonstrated that 
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neuronal nitric oxide synthase (NOS1) inhibition in the intact heart, along with the presence of increased 
myocardial Ca2+, increases an individual’s chances of Ca2+-mediated triggered arrhythmias [25]. Based 
on the aforementioned connections of nitrosylation and heart disease, we analyzed experimental and 
predicted loss of S-nitrosylation sites that are affected by nsSNVs. 
2. Experimental 
Manual curation of scientific articles retrieved using PubMed database [26] produced the 75 SNPs 
shown in Table S1. The articles selected from the PubMed database were found using search terms 
that included “Arrhythmia”, “Genome-wide”, “Association”, “Study”, “Cardiac”, and “SNP”. The 
articles published in the last 20 years were examined for reports of SNVs associated with cardiac 
arrhythmias. In these articles, SNVs discovered to have statistically significant associations with 
cardiac arrhythmias were added to the data shown in Table S1. To ensure consistency, articles that 
reported SNVs as a result of meta-analysis studies were not included in the list. Only SNVs that were 
discovered or confirmed in studies by the publishing group were eligible for inclusion. Of those SNVs, 
only those with statistically significant associations with cardiac arrhythmias were included. After 
extraction, background information on each SNV was collated from the Single Nucleotide 
Polymorphism Database or dbSNP [26] (Tables 1 and S1). This public domain archive hosts a broad 
collection of simple genetic variations. 
The seven experimentally verified S-nitrosylated cysteine sites that are affected by nsSNVs (Table 2) 
were obtained through mapping of S-nitrosylated proteins to the variations. These S-nitrosylated proteins 
were obtained from a literature review of endogenously S-nitrosylated proteins by Gould et al. [27]. 
Table 2 displays the proteins affected by the nsSNVs. Prediction of S-nitrosylation sites was performed 
as follows: the complete human proteome was obtained from UniProtKB/Swiss-Prot and GPS-SNO 
tool was used to predict N-nitrosylation sites [28]; pairwise alignments between Homo sapiens proteins 
and Mus musculus, Drosophila melanogaster, Arabidopsis thaliana and Saccharomyces cerevisiae 
proteins was performed followed by mapping of nsSNVs from SNVDis [29] to create a table that 
included predicted S-nitrosylation sites, conserved sites among the species and variation. Enrichment 
analysis was performed to identify over- or under-represented pathways or GO terms in the protein 
dataset, compared to their occurrence in the complete human proteome (Table 3). The expected 
occurrence of a pathway or GO term was calculated based on the actual number of times it was present 
in the human proteome [29,30]. Over- and under-represented pathways and processes were compared 
through significance in p values calculated based on methods described earlier [31]. 
Table 2. Loss of experimentally confirmed S-nitrosylation sites by nsSNVs. 
Protein name Position Variation Subseq Ortholog Species 
Alpha-enolase 357 c->y qackl P21550 Mouse 
Cysteine and glycine-rich protein 3 58 c->g iyckv P50462 Mouse 
Myosin-6 949 c->y decse Q02566 Mouse 
Catenin beta-1 619 c->y vlcel Q02248 Mouse 
Elongation factor 1-alpha 1 234 c->w ldcil P10126 Mouse 
Myelin proteolipid protein 220 c->y kvcgs P60202 Mouse 
E3 ubiquitin-protein ligase XIAP 90 c->y pncrf A2BGY6 Mouse 
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Table 3. Functional analysis of predicted cysteine S-nitrosylation sites with mutations. 
Analysis Functional object Observed Expected +/− p value 
PANTHER Pathways Blood Coagulation 13 3.82 + 3.64E-29 
PANTHER Protein Classification 
Receptor (includes G-protein coupled receptor) 190 123.24 + 4.13E-07 
Cytoskeletal protein 98 64.03 + 5.46E-03 
Defense/immunity protein 72 46.53 + 4.48E-02 
GO Biological Process 
Muscle contraction 73 37.48 + 1.92E-05 
Neurological system process 188 128.53 + 2.04E-05 
Cellular component organization 131 84.15 + 9.63E-05 
GO Molecular Function 
Receptor activity (includes G-protein coupled receptor activity) 190 124.18 + 6.02E-07 
Motor activity 26 9.52 + 1.05E-03 
Structural constituent of cytoskeleton 98 64.03 + 4.52E-03 
GO Cellular Component 
Cytoskeleton 98 64.03 + 1.09E-03 
Microtubule 35 17.70 + 5.89E-03 
Intracellular 107 76.44 + 1.36E-02 
3. Results and Discussion 
Table S1 is a resource for researchers or clinicians to quickly identify SNVs associated with 
arrhythmias. The inclusion of information such as flanking base pairs and exact chromosomal position 
for each of the variants in Table S1 expedites the process of testing patients if whole genome, targeted 
sequencing data or proteomics data is available. Below are details of some of the genes and variations 
associated with them that correlate to arrhythmia. 
3.1. NOS1AP 
As shown in Table 1, the gene with the most variations was NOS1AP. The NOS1AP gene is located 
on chromosome 1 at q23.3. The gene codes for a regulatory protein—carboxyl-terminal PDZ ligand of 
neuronal nitric oxide synthase [32]. The protein influences the activity of nitric oxide synthase (NOS). 
When the NOS1AP protein is expressed in the heart, cardiac repolarization is typically accelerated. 
The NOS1AP enzyme inhibits L-type calcium channels [33]. The closing of L-type calcium channels 
inhibits the influx of Ca2+ current. Consequently, intracellular calcium concentrations do not increase, 
and the beta-adrenoreceptor stimulation of the heart is suppressed. This system, starting with the 
expression of the NOS1AP protein and resulting in a change in the electrophysiology of the heart, 
helps explain the role of NOS1AP variants with QT interval duration. QT interval is a measure of 
cardiac repolarization and a common biomarker of arrhythmia. The QT interval is estimated to be 30% 
heritable [34]. Studies have shown that the noncoding variants in NOS1AP are influential [35]. This is 
consistent with the data in Table 1 where all of the NOS1AP variants are intronic. The genome-wide 
association study by Arking et al. investigated 200 individuals and found associations in these 
individuals between QT interval length and the common variants in the noncoding regions of 
NOS1AP. These findings were replicated in a community of Old Order Amish [36]. 
Due to the complexity of the biological system, it is difficult to predict how these intronic variants 
specifically influence the malfunction or mis-regulation of the NOS1AP gene. However, the presence 
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of resources such as Table S1 can help organize further inquiries into the role of intronic variants in 
disease development. 
3.2. KCNN3 
The SNV rs1131820 is a synonymous SNV found in the KCNN3 gene. The KCNN3 gene is located 
on chromosome 1q21 and is responsible for coding the protein SK3. The protein SK3 belongs  
to a family of proteins that operate as calcium activated potassium channels. Specifically, SK3 is a 
small-conductance calcium activated potassium channel [37]. This indicates that SK3 is voltage 
insensitive and the opening of the channel is instead reliant on the presence of calcium ions. The 
protein plays a role after hyper-polarization, a calcium dependent process that is executed after the 
firing of an action potential in a neuron. A variant in KCNN3 may influence the regulation or function 
of the SK3 protein. Reduced efficacy of the SK3 protein can inhibit influx of potassium ions through 
the potassium channel across a membrane. This can disrupt firing of the neuron. Consequently, 
KCNN3 variants expressed in regions such as the brain or the heart can have significant consequences 
on those delicate biological systems. 
In the heart, a KCNN3 variant was shown to have an association with lone atrial fibrillation. This 
SNP rs1131820, shown in Table 1 is synonymous. This indicates that there is no consequent change in 
amino acid from the base pair mutation. One would anticipate that without a change in the amino acid, 
the effects of a variation would not manifest. However, in this circumstance, a carrier of the two major 
alleles GG at rs1131820 had an odds ratio of 2.85 (95% CI 1.13–7.18, p = 0.026) for lone atrial 
fibrillation when compared to carriers of the minor allele AA [38]. This suggests that carriers of the 
two major alleles GG are nearly three times more likely to develop lone atrial fibrillation. It is still 
unclear how a synonymous SNP can drastically increase the likelihood of an individual developing a 
disease or condition. Recent research has shown that these silent variations may affect the affinity of 
RNA binding proteins for mRNA, the splicing of pre-mRNA, and the stability of pre-mRNA [39–41]. 
This, in turn, may compromise the structure of the mRNA, and consequently influence protein 
formation, efficacy or concentration [42,43]. Once protein function or concentration has been altered, 
action potential firing in the heart can be disrupted and lead to the development of atrial fibrillation. 
3.3. Analysis of Exonic SNVs 
The exonic SNVs shown in Table 1 were explored further using the NHLBI Exome Sequencing 
Project (ESP). This project is a collaborative effort between various institutions and research hospitals 
to use NGS of the human exome to discover new genes and the mechanisms through which they 
influence the development of heart, blood, and lung disorders. The project expands across diverse 
populations and facilitates the sharing of conclusions and datasets throughout the scientific community 
(Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, USA [44].  
11 exonic SNVs in the ESP database were searched. The new noteworthy information that the ESP 
database yielded for each SNV included variation impact analysis values. This value helps predict the 
likely impact of an amino acid substitution on protein structure and function [45]. The PolyPhen-2 
scores for the variants ranged from benign 0.0 for the SNVs rs6795970, rs180514, rs1805127, 
rs12621643, and rs1800172—to possibly damaging 0.952 for SNV rs1805123. A score of benign 
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suggests that the amino acid substitutions in each of these SNPs have no serious consequences on 
protein function. However, rs679570 was associated with time changes in the electrical cycles of the 
heart and an increased risk of heart block [46]. Conversely, rs846111 was associated with changes in 
the Q-T interval of the heart [47]. Finally, although rs113180 was not assigned a PolyPhen-2 score, 
this synonymous SNP is associated with a nearly three times higher likelihood of an individual 
developing lone atrial fibrillation [38]. 
3.4. Non-Synonymous Variation 
Table 1 shows ten nsSNVs, one is a variant in a gene that encodes a ring finger protein, the other 
nine SNVs are found in genes that encode sodium ion channels or potassium voltage-gated channels. 
The two sodium ion channel genes are SCN10A and SCN5A. They are the type X and type V  
voltage-gated sodium channels, respectively. Table 1 shows that the SCN5A gene hosts two nsSNVs. 
The first is an amino acid substitution from serine to tyrosine at position 1103. The second is an amino 
acid substitution from histidine to arginine at position 558. The gene SCN10A contains the SNV 
rs6795970, an A/G base pair polymorphism at chromosome 3 position 38766675. This mutation in the 
exonic region results in an amino acid change from valine to alanine at position 1073. The specific 
voltage-gated sodium channel is labeled Nav1.8 and the protein is more commonly known for its role 
in facilitating cold perception in afferent nociceptive fibers [1]. Despite the association of this SNV 
with cardiac arrhythmias, the role of the Nav1.8 sodium channel in the electrophysiology of the  
heart is still uncharacterized [2]. The influence of the amino acid substitution on the function of the 
voltage-gated sodium channel is still unknown. 
The genes found with nsSNVs that code for potassium voltage-gated channels are KCNE1, 
KCNH2, KCNQ1, and KCNE4. KCNH2 and KCNQ1, found in chromosome 7 and 11 respectively, 
are genes whose variants have been associated with long QT syndrome [48,49]. In KCNH2, the two 
nsSNVs are substitutions from lysine to threonine at amino acid positions 897 and 557. In KCNQ1, the 
variant results in an amino acid substitution from glycine to serine at position 643. The final two 
genes, KCNE1 and KCNE4 are found on chromosome 21 and 2, respectively. They belong to the 
KCNE family of genes, which encode trans-membrane proteins with a wide array of functions. Each of 
these genes contains non-synonymous SNPs that have associations with cardiac arrhythmias [50,51]. 
The RNF207 gene codes for a ring finger protein and contains the variant rs846111. This variant is 
found on chromosome 1 position 6279370. RNF207 codes for ring finger protein 207. The protein plays 
a role in intracellular zinc ion binding [3]. The specific in vivo function of the protein is still unknown. 
Although it is known that the variation translates to a shift of glycine to alanine at position 603, the 
specific influences of this amino acid substitution on the protein’s function are not yet understood. 
3.5. Nitrosylation 
PTMs such as glycosylation, phosphorylation, and nitrosylation help maintain cardiac rhythm, and 
modulate gating, localization, and cardiac channel expression levels [12]. To identify additional 
variations potentially connected to cardiac arrhythmias, we investigated the PTM Nitrosylation. Nitric 
oxide (NO) is synthesized by a majority of cardiac cell types and plays a vital role in regulating cardiac 
function [52]. The effects of NO are moderated by S-nitrosylation, which is the covalent modification 
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of a protein cysteine thiol by an NO group to generate an S-nitrosothiol (SNO) [53]. The fundamental 
roles for S-nitrosylation have been involved in major functions of NO in the cardiovascular system [53]. 
Gould et al. performed a literature search for S-nitrosylated proteins in vivo [27]. The 233  
S-nitrosylated proteins they compiled display an over-representation of mitochondrial proteins, a 
significant proportion involved in the generation of precursor metabolites and energy, and pathological 
conditions associated with an overproduction of NO, which results in inappropriate S-nitroyslation and 
dysfunction of proteins [27]. To further understand which nitrosylated proteins were affected by 
variation, we mapped the nitrosylation sites of 233 S-nitrosylated proteins to non-synonymous 
variations. We found seven cysteines that have loss of S-nitrosylation sites due to nsSNVs (Table 2). 
Myosin, a motor protein listed in Table 2, plays a role in regulation of the heartbeat and cardiac 
function. Studies have shown that mutations of the cardiac myosin gene are the most common cause of 
inherited hypertrophic cardiomyopathy [54]. Nearly 200 disease-associated myosin mutations have 
been identified since the discovery of the  cardiac myosin heavy-chain (-MHC) gene missense 
mutation’s role in hypertrophic cardiomyopathy [54,55]. -MHC is a sarcomeric protein expressed in 
the right and left ventricles of the heart, as well as many skeletal muscles [56]. The precise location of 
the mutation or alteration of the myosin gene appears to influence the survival of patients; further 
investigation of this variation may lead to better prognostics for people affected by the mutation [55]. 
The current list of experimentally verified nitrosylation sites is not comprehensive. Table S2 
contains the list of 1429 proteins which have conserved cysteines across eukaryotic species predicted 
to be S-nitrosylated and affected by nsSNPs and Figure 1 shows that several of these sites have 
nsSNVs. To better understand the distribution of predicted S-nitroyslation sites with conserved motifs, 
we analyzed the dataset to observe if there was over- or under-representation (compared to the 
complete human proteome) of pathways and functional elements/biological processes. An initial analysis 
using the UniProtKB/Swiss-Prot keyword ‘Disease’ showed that the keyword was over-represented in the 
predicted list of S-nitrosylated proteins (observed: 356; expected: 196.96; p-value: 3.64E-29). The highly 
significant p value proved that there are a higher number of disease proteins that are present in Table S2. 
For several of the known or predicted S-nitrosylation sites that are lost due to nsSNVs we were able to 
identify diseases associated with these variations (examples—dbSNP id: rs104894204, gene: CSRP3, 
UniProt AC/position/variation: P50461/58/c->g, disease: familial hypertrophic cardiomyopathy type 12; 
dbSNP id: rs121909300, gene: OXCT1, UniProt AC/position/variation: P55809/456/c->f, disease: 
succinyl-coa-3-ketoacid-coa transferase deficiency; dbSNP id: rs121909267, gene: CASR, UniProt 
AC/position/variation: P41180/131/c->w, disease: familial isolated hypoparathyroidism). S-nitrosylation 
has not yet been directly connected to these diseases and hence sites such as these (additional ones 
available in Table S2) are ideal for further biochemical analysis to elucidate the role of S-nitrosylation 
in cardiac and other diseases. 
The PANTHER gene ontology database [57] determined if the predicted loss of S-nitrosylation sites 
affected by nsSNVs were statistically enriched with a particular molecular function or biological 
process. Over- and under-representation of PANTHER Pathways, Protein Classification, and Gene 
Ontology (GO) terms in the predicted list of mutated cysteines, provided an overview of possible 
effects these non-synonymous variations might have. Table 3 contains the results of the PANTHER 
statistical overrepresentation test. The major pathway identified as over-represented is blood 
coagulation (observed: 13; expected: 3.82; p-value: 3.64E-29). Atrial Fibrillation, a common type of 
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arrhythmia, can lead to blood clots and other complications. Antithrombotic prophylaxis for stroke, a 
major risk of atrial fibrillation, is associated with an increased risk of bleeding [58]. 
Figure 1. Percentage of predicted S-nitrosylated proteins and sites and the ones which are 
conserved across mouse, fly, plant or yeast and the nsSNVs mapped to these proteins and 
sites. Details are available in Table S2. 
 
The major broad terms for Gene Ontology (GO) Biological Processes that were statistically  
over-represented were Muscle Contraction, Neurological System Process, and Cellular Organization. 
For GO Molecular Function, the major terms included receptor activity (includes G-protein coupled 
receptor activity), motor activity, and structural constituent of cytoskeleton. The cytoskeleton was the 
top over-represented GO cellular component (p-value: 1.09E-03). The cytoskeleton of cardiac myocytes 
consists of actin filaments, intermediate filaments, and alpha- and beta-tubulin that form the 
microtubules by polymerization [59]. Studies have shown that the extra-sarcomeric cytoskeleton plays 
a part in the growth response of the heart and in the pathogenesis of cardiomyopathies [60]. Acquired 
forms of heart failure have displayed an altered expression of cytoskeletal proteins [61]. 
Microtubules were also statistically over-represented in GO cellular components (p-value: 5.89E-03). 
Recent studies have investigated the role of microtubules in cardiac arrhythmias. In hypertrophy and 
heart failure, the accumulation of microtubules disrupts sarcomere motion, contributing to declining 
ventricular compliance [61]. Microtubule integrity has been linked to cardio-protection, while 
microtubule disruption has been associated in the response to ischemia in cardiac myocytes [62]. 
3.6. Next-Generation Sequencing and Variation 
As the cost of exome sequencing decreases, the use of patient exome sequencing will increase as a 
diagnostic tool. Here we describe a possible workflow for identifying variation from NGS data using a 
High-performance Integrated Virtual Environment (HIVE), a cloud-based environment [63]. 
The FASTA sequences surrounding a SNV are obtained from dbSNP by querying the database 
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Proteins 20261 14054 11718 1429
Number of 
Sites 260120 33327 24578 1598
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Destination” ≥ “FASTA”. This file is then uploaded to HIVE and used as a reference to which NGS 
data from an individual can be mapped (for additional details see help section on HIVE). Once the 
input files (FASTA file downloaded from dbSNP and NGS data obtained from an individual) are 
selected then HIVE-hexagon, a sequence mapping algorithm, is used with default parameters to map 
the NGS reads to the FASTA record which has the SNV in it. Once the mapping is complete then 
HIVE-pentagon, a SNV profiling tool, is used to identify all the variations in the individual. 
Visualization of the mapping results provides an easy overview of the variations present in the 
individual an example of which is shown in Figure 2. 
Figure 2. HIVE interface showing results obtained from SNV profiling of human exome 
reads mapped to FASTA sequence surrounding a SNV. (A) Overall coverage result with 
the 603 position showing variation. (B) Reads mapped to the reference with the yellow 
highlighting the column selected. (C) Only variations are shown in this panel.  
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4. Conclusions 
We expect that as whole genome sequencing becomes more affordable, genetic testing will play a 
larger role in the diagnosis of cardiac disorders, and that resources such as Table S1 will become more 
valuable and common place. In addition to their capacity to sequence whole genomes, the NGS 
platforms are capable of targeted sequencing. Table S1 also contains nucleotides that are upstream and 
downstream of each variant. This information allows researchers or physicians to quickly generate 
libraries of nucleic acids as the primary step in creation of a template. There is currently no quick and 
easy way to compile a list of variations that have associations with a condition or disease. This table 
provides a solution for this gap through manual curation. Rather than having physicians and 
researchers sift through papers to isolate SNPs that are associated with diseases, they can simply create 
a library of nucleic acids using the information contained in the table. These libraries can then be 
clonally amplified and their fragments can be prepared specifically per the requirements of the various 
NGS platforms. The list of these variations is also available from the BioMuta database [64]. It is 
important to note that DNA variants are rarely the sole determinant of whether an individual will 
acquire a disease or not. Consequently, it is important that healthcare workers as well as patients 
remember that these SNVs are a single parameter in a complex biological system. An additional 
danger that arises from sequencing patients as a diagnostic tool is the incidental discovery of presumed 
deleterious mutations [65].  
In an attempt to identify more variants potentially connected to the disease, we investigated the 
post-translational modification nitrosylation in depth. Many studies have examined potential 
associations between acquired arrhythmias and post-translational modifications, such as glycosylation, 
phosphorylation, and nitrosylation. Tables 2 and 3 provide both experimental and predicted approaches 
for discovering loss of S-nitrosylation sites that are affected by nsSNVs and details of the amino acid 
changes are present in Table S2. This information can be used to develop proteomic strategies for 
variation detection. 
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Table S2. Predicted S-nitrosylation sites, which are conserved in other eukaryotes and have  
non-synonymous variations. 
Acknowledgments 
This project is supported in part by Research Participation Program at the Center for Biologics 
Evaluation and Research administered by the Oak Ridge Institute for Science and Education  
through an interagency agreement between the U.S. Department of Energy and the U.S. Food and 
Drug Administration. 
  
Genes 2014, 5 265 
 
Author Contributions 
Conceived and designed the study: Raja Mazumder. Performed the study: Ayman Abunimer and 
Phuc Lam. Analyzed the data: Ayman Abunimer, Krista Smith, Tsung-Jung Wu, and Phuc Lam. 
Contributed tools: Vahan Simonyan. Wrote the paper: Ayman Abunimer and Krista Smith. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Darbar, D. Genomics, heart failure and sudden cardiac death. Heart Fail. Rev. 2010, 15, 229–238. 
2. Mahida, S.; Lubitz, S.A.; Rienstra, M.; Milan, D.J.; Ellinor, P.T. Monogenic atrial fibrillation as 
pathophysiological paradigms. Cardiovasc. Res. 2011, 89, 692–700. 
3. Parvez, B.; Darbar, D. The “missing” link in atrial fibrillation heritability. J. Electrocardiol. 2011, 
44, 641–644. 
4. Biesecker, L.G. Opportunities and challenges for the integration of massively parallel genomic 
sequencing into clinical practice: Lessons from the clinseq project. Genet. Med. 2012, 14,  
393–398. 
5. Ng, D.; Johnston, J.J.; Teer, J.K.; Singh, L.N.; Peller, L.C.; Wynter, J.S.; Lewis, K.L.; Cooper, 
D.N.; Stenson, P.D.; Mullikin, J.C.; et al. Interpreting secondary cardiac disease variants in an 
exome cohort. Circ. Cardiovasc. Genet. 2013, 6, 337–346. 
6. Yang, Y.; Muzny, D.M.; Reid, J.G.; Bainbridge, M.N.; Willis, A.; Ward, P.A.; Braxton, A.; 
Beuten, J.; Xia, F.; Niu, Z.; et al. Clinical whole-exome sequencing for the diagnosis of 
mendelian disorders. N. Engl. J. Med. 2013, 369, 1502–1511. 
7. Gonzaga-Jauregui, C.; Lupski, J.R.; Gibbs, R.A. Human genome sequencing in health and 
disease. Annu. Rev. Med. 2012, 63, 35–61. 
8. Moore, B.; Hu, H.; Singleton, M.; de la Vega, F.M.; Reese, M.G.; Yandell, M. Global analysis of  
disease-related DNA sequence variation in 10 healthy individuals: Implications for whole 
genome-based clinical diagnostics. Genet. Med. 2011, 13, 210–217. 
9. Priori, S.G.; Barhanin, J.; Hauer, R.N.; Haverkamp, W.; Jongsma, H.J.; Kleber, A.G.; McKenna, 
W.J.; Roden, D.M.; Rudy, Y.; Schwartz, K.; et al. Genetic and molecular basis of cardiac 
arrhythmias: Impact on clinical management parts I and II. Circulation 1999, 99, 518–528. 
10. Camm, A.J.; Janse, M.J.; Roden, D.M.; Rosen, M.R.; Cinca, J.; Cobbe, S.M. Congenital and 
acquired long qt syndrome. Eur. Heart J. 2000, 21, 1232–1237. 
11. Marban, E. Cardiac channelopathies. Nature 2002, 415, 213–218. 
12. Jagu, B.; Charpentier, F.; Toumaniantz, G. Identifying potential functional impact of mutations 
and polymorphisms: Linking heart failure, increased risk of arrhythmias and sudden cardiac 
death. Front. Physiol. 2013, 4, 254. 
13. Noble, D. Modeling the heart—From genes to cells to the whole organ. Science 2002, 295,  
1678–1682. 
Genes 2014, 5 266 
 
14. Mayne, J.; Starr, A.E.; Ning, Z.; Chen, R.; Chiang, C.K.; Figeys, D. Fine tuning of proteomic 
technologies to improve biological findings: Advancements in 2011–2013. Anal. Chem. 2014, 86, 
175–195. 
15. Li, J.; Su, Z.; Ma, Z.Q.; Slebos, R.J.; Halvey, P.; Tabb, D.L.; Liebler, D.C.; Pao, W.; Zhang, B.  
A bioinformatics workflow for variant peptide detection in shotgun proteomics. Mol. Cell. 
Proteomics 2011, doi:10.1074/mcp.M110.006536. 
16. Butter, F.; Davison, L.; Viturawong, T.; Scheibe, M.; Vermeulen, M.; Todd, J.A.; Mann, M. 
Proteome-wide analysis of disease-associated snps that show allele-specific transcription factor 
binding. PLoS Genet. 2012, 8, e1002982. 
17. Eisenberg, E.; Adamsky, K.; Cohen, L.; Amariglio, N.; Hirshberg, A.; Rechavi, G.; Levanon, 
E.Y. Identification of rna editing sites in the snp database. Nucleic Acids Res. 2005, 33,  
4612–4617. 
18. Bunger, M.K.; Cargile, B.J.; Sevinsky, J.R.; Deyanova, E.; Yates, N.A.; Hendrickson, R.C.;  
Stephenson, J.L., Jr. Detection and validation of non-synonymous coding snps from orthogonal 
analysis of shotgun proteomics data. J. Proteome Res. 2007, 6, 2331–2340. 
19. Hess, D.T.; Matsumoto, A.; Kim, S.O.; Marshall, H.E.; Stamler, J.S. Protein S-nitrosylation: 
Purview and parameters. Nature Rev.. Mol. Cell Biol. 2005, 6, 150–166. 
20. Bian, K.; Doursout, M.F.; Murad, F. Vascular system: Role of nitric oxide in cardiovascular 
diseases. J. Clin. Hypertens. 2008, 10, 304–310. 
21. Greco, T.M.; Hodara, R.; Parastatidis, I.; Heijnen, H.F.; Dennehy, M.K.; Liebler, D.C.; 
Ischiropoulos, H. Identification of S-nitrosylation motifs by site-specific mapping of the  
S-nitrosocysteine proteome in human vascular smooth muscle cells. Proc. Nat. Acad. Sci. USA 
2006, 103, 7420–7425. 
22. Massy, Z.A.; Fumeron, C.; Borderie, D.; Tuppin, P.; Nguyen-Khoa, T.; Benoit, M.O.; Jacquot, C.; 
Buisson, C.; Drueke, T.B.; Ekindjian, O.G.; et al. Increased pasma S-nitrosothiol concentrations 
predict cardiovascular outcomes among patients with end-stage renal disease: A prospective 
study. J. Am. Soc. Nephrol. 2004, 15, 470–476. 
23. Datta, B.; Tufnell-Barrett, T.; Bleasdale, R.A.; Jones, C.J.; Beeton, I.; Paul, V.; Frenneaux, M.; 
James, P. Red blood cell nitric oxide as an endocrine vasoregulator: A potential role in congestive 
heart failure. Circulation 2004, 109, 1339–1342. 
24. Herren, A.W.; Bers, D.M.; Grandi, E. Post-translational modifications of the cardiac na channel: 
Contribution of camkii-dependent phosphorylation to acquired arrhythmias. American J. Physiol. 
Heart Circ. Physiol. 2013, 305, H431–H445. 
25. Cutler, M.J.; Plummer, B.N.; Wan, X.; Sun, Q.A.; Hess, D.; Liu, H.; Deschenes, I.; Rosenbaum, 
D.S.; Stamler, J.S.; Laurita, K.R. Aberrant s-nitrosylation mediates calcium-triggered ventricular 
arrhythmia in the intact heart. Proc. Nat. Acad. Sci. USA 2012, 109, 18186–18191. 
26. Sayers, E.W.; Barrett, T.; Benson, D.A.; Bolton, E.; Bryant, S.H.; Canese, K.; Chetvernin, V.; 
Church, D.M.; Dicuccio, M.; Federhen, S.; et al. Database resources of the national center for 
biotechnology information. Nucleic Acids Res. 2012, 40, D13–D25. 
27. Gould, N.; Doulias, P.T.; Tenopoulou, M.; Raju, K.; Ischiropoulos, H. Regulation of  
protein function and signaling by reversible cysteine S-nitrosylation. J. Biol. Chem 2013, 288, 
26473–26479. 
Genes 2014, 5 267 
 
28. Xue, Y.; Liu, Z.; Gao, X.; Jin, C.; Wen, L.; Yao, X.; Ren, J. Gps-sno: Computational prediction of 
protein S-nitrosylation sites with a modified gps algorithm. PLoS One 2010, 5, e11290. 
29. Karagiannis, K.; Simonyan, V.; Mazumder, R. Snvdis: A proteome-wide analysis service for 
evaluating nssnvs in protein functional sites and pathways. Genomics Proteomics Bioinformatics 
2013, 11, 122–126. 
30. Mazumder, R.; Morampudi, K.S.; Motwani, M.; Vasudevan, S.; Goldman, R. Proteome-wide 
analysis of single-nucleotide variations in the n-glycosylation sequon of human genes. PLoS One 
2012, 7, e36212. 
31. Mi, H.; Thomas, P. Panther pathway: An ontology-based pathway database coupled with data 
analysis tools. Methods Mol. Biol. 2009, 563, 123–140. 
32. Earle, N.; Yeo Han, D.; Pilbrow, A.; Crawford, J.; Smith, W.; Shelling, A.N.; Cameron, V.;  
Love, D.R.; Skinner, J.R. Single nucleotide polymorphisms in arrhythmia genes modify the risk 
of cardiac events and sudden death in long qt syndrome. Heart Rhythm 2013, 11, 76–82. 
33. Chang, K.C.; Barth, A.S.; Sasano, T.; Kizana, E.; Kashiwakura, Y.; Zhang, Y.; Foster, D.B.; 
Marban, E. Capon modulates cardiac repolarization via neuronal nitric oxide synthase signaling in 
the heart. Proc. Nat. Acad. Sci. USA 2008, 105, 4477–4482. 
34. Arking, D.E.; Pfeufer, A.; Post, W.; Kao, W.H.; Newton-Cheh, C.; Ikeda, M.; West, K.; Kashuk, C.; 
Akyol, M.; Perz, S.; et al. A common genetic variant in the nos1 regulator nos1ap modulates 
cardiac repolarization. Nat. Genet. 2006, 38, 644–651. 
35. Wratten, N.S.; Memoli, H.; Huang, Y.; Dulencin, A.M.; Matteson, P.G.; Cornacchia, M.A.; 
Azaro, M.A.; Messenger, J.; Hayter, J.E.; Bassett, A.S.; et al. Identification of a schizophrenia-
associated functional noncoding variant in nos1ap. Am. J. Psychiatry 2009, 166, 434–441. 
36. Post, W.; Shen, H.; Damcott, C.; Arking, D.E.; Kao, W.H.; Sack, P.A.; Ryan, K.A.; Chakravarti, 
A.; Mitchell, B.D.; Shuldiner, A.R. Associations between genetic variants in the nos1ap (capon) 
gene and cardiac repolarization in the old order amish. Hum. Hered. 2007, 64, 214–219. 
37. Ellinor, P.T.; Lunetta, K.L.; Glazer, N.L.; Pfeufer, A.; Alonso, A.; Chung, M.K.; Sinner, M.F.;  
de Bakker, P.I.; Mueller, M.; Lubitz, S.A.; et al. Common variants in kcnn3 are associated with 
lone atrial fibrillation. Nat. Genet. 2010, 42, 240–244. 
38. Olesen, M.S.; Jabbari, J.; Holst, A.G.; Nielsen, J.B.; Steinbruchel, D.A.; Jespersen, T.; Haunso, S.; 
Svendsen, J.H. Screening of kcnn3 in patients with early-onset lone atrial fibrillation. Europace 
2011, 13, 963–967. 
39. Sauna, Z.E.; Kimchi-Sarfaty, C.; Ambudkar, S.V.; Gottesman, M.M. The sounds of silence: 
Synonymous mutations affect function. Pharmacogenomics 2007, 8, 527–532. 
40. Hunt, R.; Sauna, Z.E.; Ambudkar, S.V.; Gottesman, M.M.; Kimchi-Sarfaty, C. Silent (synonymous) 
snps: Should we care about them? Methods Mol. Biol. 2009, 578, 23–39. 
41. Chamary, J.V.; Parmley, J.L.; Hurst, L.D. Hearing silence: Non-neutral evolution at synonymous 
sites in mammals. Nat. Rev. Genet. 2006, 7, 98–108. 
42. Purvis, I.J.; Bettany, A.J.; Santiago, T.C.; Coggins, J.R.; Duncan, K.; Eason, R.; Brown, A.J. The 
efficiency of folding of some proteins is increased by controlled rates of translation in vivo. A 
hypothesis. J. Mol. Biol.1987, 193, 413–417. 
Genes 2014, 5 268 
 
43. Nackley, A.G.; Shabalina, S.A.; Tchivileva, I.E.; Satterfield, K.; Korchynskyi, O.; Makarov, S.S.; 
Maixner, W.; Diatchenko, L. Human catechol-o-methyltransferase haplotypes modulate protein 
expression by altering mrna secondary structure. Science 2006, 314, 1930–1933. 
44. HLBI_Exome_Sequencing_Project. Exome Variant Server. Avaiblale online: http://evs.gs.washington. 
edu/EVS/ (accessed on 9 January 2013).  
45. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.; 
Kondrashov, A.S.; Sunyaev, S.R. A method and server for predicting damaging missense 
mutations. Nat. Methods 2010, 7, 248–249. 
46. Chambers, J.C.; Zhao, J.; Terracciano, C.M.; Bezzina, C.R.; Zhang, W.; Kaba, R.; Navaratnarajah, 
M.; Lotlikar, A.; Sehmi, J.S.; Kooner, M.K.; et al. Genetic variation in scn10a influences cardiac 
conduction. Nat. Genet. 2010, 42, 149–152. 
47. Pfeufer, A.; Sanna, S.; Arking, D.E.; Muller, M.; Gateva, V.; Fuchsberger, C.; Ehret, G.B.;  
Orru, M.; Pattaro, C.; Kottgen, A.; et al. Common variants at ten loci modulate the qt interval 
duration in the qtscd study. Nat. Genet. 2009, 41, 407–414. 
48. Pfeufer, A.; Jalilzadeh, S.; Perz, S.; Mueller, J.C.; Hinterseer, M.; Illig, T.; Akyol, M.; Huth, C.;  
Schopfer-Wendels, A.; Kuch, B.; et al. Common variants in myocardial ion channel genes modify 
the qt interval in the general population: Results from the kora study. Circ. Res. 2005, 96,  
693–701. 
49. Ozawa, T.; Ito, M.; Tamaki, S.; Yao, T.; Ashihara, T.; Kita, Y.; Okamura, T.; Ueshima, H.; Horie, M. 
Gender and age effects on ventricular repolarization abnormality in japanese general carriers of a 
g643s common single nucleotide polymorphism for the kcnq1 gene. Circ. J. Offic. J. Jpn. Circ. 
Soc. 2006, 70, 645–650. 
50. Zeng, Z.Y.; Pu, J.L.; Tan, C.; Teng, S.Y.; Chen, J.H.; Su, S.Y.; Zhou, X.Y.; Zhang, S.; Li, Y.S.;  
Wang, F.Z.; et al. The association of single nucleotide polymorphism of slow delayed rectifier k+ 
channel genes with atrial fibrillation in han nationality chinese. Zhonghua Xin Xue Guan Bing Za Zhi 
2005, 33, 987–991. 
51. Olszak-Waskiewicz, M.; Kubik, L.; Dziuk, M.; Sidlo, E.; Kucharczyk, K.; Kaczanowski, R. The 
association between scn5a, kcnq1 and kcne1 gene polymorphisms and complex ventricular 
arrhythmias in survivors of myocardial infarction. Kardiol. Pol. 2008, 66, 845–853. 
52. Tamargo, J.; Caballero, R.; Gomez, R.; Delpon, E. Cardiac electrophysiological effects of nitric 
oxide. Cardiovasc. Res. 2010, 87, 593–600. 
53. Lima, B.; Forrester, M.T.; Hess, D.T.; Stamler, J.S. S-nitrosylation in cardiovascular signaling. 
Circ. Res. 2010, 106, 633–646. 
54. Herron, T.J.; Devaney, E.J.; Metzger, J.M. Modulation of cardiac performance by motor protein 
gene transfer. Ann. N. Y. Acad. Sci. 2008, 1123, 96–104. 
55. Watkins, H.; Rosenzweig, A.; Hwang, D.S.; Levi, T.; McKenna, W.; Seidman, C.E.; Seidman, J.G. 
Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic 
cardiomyopathy. N. Engl. J. Med. 1992, 326, 1108–1114. 
56. Yu, Q.T.; Ifegwu, J.; Marian, A.J.; Mares, A., Jr.; Hill, R.; Perryman, M.B.; Bachinski, L.L.; 
Roberts, R. Hypertrophic cardiomyopathy mutation is expressed in messenger rna of skeletal as 
well as cardiac muscle. Circulation 1993, 87, 406–412. 
Genes 2014, 5 269 
 
57. Mi, H.; Lazareva-Ulitsky, B.; Loo, R.; Kejariwal, A.; Vandergriff, J.; Rabkin, S.; Guo, N.; 
Muruganujan, A.; Doremieux, O.; Campbell, M.J.; et al. The panther database of protein families, 
subfamilies, functions and pathways. Nucleic Acids Res. 2005, 33, D284–D288. 
58. You, J.J.; Singer, D.E.; Howard, P.A.; Lane, D.A.; Eckman, M.H.; Fang, M.C.; Hylek, E.M.; 
Schulman, S.; Go, A.S.; Hughes, M.; et al. Antithrombotic therapy for atrial fibrillation: 
Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest 
physicians evidence-based clinical practice guidelines. Chest 2012, 141, e531S–e575S. 
59. Hein, S.; Kostin, S.; Heling, A.; Maeno, Y.; Schaper, J. The role of the cytoskeleton in heart 
failure. Cardiovasc. Res. 2000, 45, 273–278. 
60. Roberts, R.; Schwartz, K. Myocardial diseases. Circulation 2000, 102, IV34–IV39. 
61. Heling, A.; Zimmermann, R.; Kostin, S.; Maeno, Y.; Hein, S.; Devaux, B.; Bauer, E.; Klovekorn, 
W.P.; Schlepper, M.; Schaper, W.; et al. Increased expression of cytoskeletal, linkage, and 
extracellular proteins in failing human myocardium. Circ. Res. 2000, 86, 846–853. 
62. Xiao, J.; Cao, H.; Liang, D.; Liu, Y.; Zhang, H.; Zhao, H.; Li, J.; Yan, B.; Peng, L.; Zhou, Z.; et al. 
Taxol, a microtubule stabilizer, prevents ischemic ventricular arrhythmias in rats. J. Cell. Mol. 
Med. 2011, 15, 1166–1176. 
63. Simonyan, V.; Mazumder, R. High-performance integrated virtual environment clouds (hive) for  
extra-large (xl) data analysis. Comparative sequence, genome analysis, genome assembly, & 
genome scale computational methods session. In the Proceesings of the 2011 International 
Conference on Bioinformatics and Computational Biology, Las Vegas, NV, USA, 17–21 July 2011. 
64. Wu, T.-J.; Shamsaddini, A.; Pan, Y.; Smith, K.; Crichton, D.; Simonyan, V.; Mazumder, R. A 
framework for organizing cancer related variations from existing databases, publications and ngs 
data using a high-performance integrated virtual environment (HIVE). Database 2014, in press. 
65. Johnston, J.J.; Rubinstein, W.S.; Facio, F.M.; Ng, D.; Singh, L.N.; Teer, J.K.; Mullikin, J.C.; 
Biesecker, L.G. Secondary variants in individuals undergoing exome sequencing: Screening of 
572 individuals identifies high-penetrance mutations in cancer-susceptibili ty genes. Am. J. Hum. 
Genet. 2012, 91, 97–108. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
